348 related articles for article (PubMed ID: 33376063)
1. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
[TBL] [Abstract][Full Text] [Related]
3. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
5. MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study.
Białek Ł; Czerwińska K; Fus Ł; Krajewski W; Sadowska A; Radziszewski P; Dobruch J; Kryst P; Poletajew S
Cancer Biomark; 2021; 30(2):139-143. PubMed ID: 32924986
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
7. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
[TBL] [Abstract][Full Text] [Related]
8. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
[TBL] [Abstract][Full Text] [Related]
9. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
Pierconti F; Martini M; Cenci T; Fiorentino V; Gianfrancesco LD; Ragonese M; Bientinesi R; Rossi E; Larocca LM; Racioppi M; Bassi PF
Urol Oncol; 2022 Mar; 40(3):108.e19-108.e25. PubMed ID: 34903453
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
[TBL] [Abstract][Full Text] [Related]
11. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
Ragonese M; Gianfrancesco LD; Palermo G; Pierconti F; Martini M; Foti M; Bassi P; Racioppi M
Clin Genitourin Cancer; 2022 Aug; 20(4):e271-e275. PubMed ID: 35871875
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.
Roupret M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Sylvester R; Longo F; Montanari E; Palou J
J Urol; 2020 Oct; 204(4):685-690. PubMed ID: 32314931
[TBL] [Abstract][Full Text] [Related]
13. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
Hekman MCH; Wijn SRW; Lotan Y; Govers TM; Witjes JA
World J Urol; 2023 Feb; 41(2):471-476. PubMed ID: 36534153
[TBL] [Abstract][Full Text] [Related]
14. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
15. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.
Dudderidge T; Stockley J; Nabi G; Mom J; Umez-Eronini N; Hrouda D; Cresswell J; McCracken SRC
Eur Urol Oncol; 2020 Feb; 3(1):42-46. PubMed ID: 31307961
[TBL] [Abstract][Full Text] [Related]
16. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
17. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
Territo A; Gallioli A; Diana P; Boissier R; Fontana M; Gaya JM; Sanguedolce F; Calderón J; Piana A; Fontanet S; Algaba F; Palou J; Breda A
J Urol; 2022 Sep; 208(3):570-579. PubMed ID: 35549312
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
